open access

Vol 3, No 6 (2007)
Guidelines / Expert consensus
Published online: 2008-05-08
Get Citation

Systemic therapy of colorectal cancer - consensus based on the results of clinical trials

Maciej Krzakowski, Krzysztof Bujko, Kazimierz Drosik, Jacek Jassem, Krzysztof Krzemieniecki, Marek Wojtukiewicz
Onkol. Prak. Klin 2007;3(6):267-285.

open access

Vol 3, No 6 (2007)
EXPERTS' OPINION
Published online: 2008-05-08

Abstract

Colorectal cancer represents a major health problem in Poland, accounting for over 13 000 new cases diagnosed annually. The treatment options in colorectal cancer have evolved significantly over the last decade, with several new cytotoxic and molecularly targeted agents approved for the treatment of this disease. These advances have brought a clear improvement in survival of patients. The efficacy of new cytotoxic drugs (irinotecan, oxaliplatin and oral fluoropyrimidines), both in the adjuvant and palliative settings, have been confirmed in the randomised studies. The advent of monoclonal antibodies (bevacizumab, cetuximab and panitumumab) may further broaden the scope of therapeutic methods in metastatic disease, however the clinical application of these compounds is still limited. Despite these achievements, the oncology community still awaits answers to numerous questions on the optimal use of newly developed systemic treatment options. This article reviews available options of systemic therapy with the aim of assisting clinicians in their daily practice.

Abstract

Colorectal cancer represents a major health problem in Poland, accounting for over 13 000 new cases diagnosed annually. The treatment options in colorectal cancer have evolved significantly over the last decade, with several new cytotoxic and molecularly targeted agents approved for the treatment of this disease. These advances have brought a clear improvement in survival of patients. The efficacy of new cytotoxic drugs (irinotecan, oxaliplatin and oral fluoropyrimidines), both in the adjuvant and palliative settings, have been confirmed in the randomised studies. The advent of monoclonal antibodies (bevacizumab, cetuximab and panitumumab) may further broaden the scope of therapeutic methods in metastatic disease, however the clinical application of these compounds is still limited. Despite these achievements, the oncology community still awaits answers to numerous questions on the optimal use of newly developed systemic treatment options. This article reviews available options of systemic therapy with the aim of assisting clinicians in their daily practice.
Get Citation

Keywords

colorectal cancer; systemic therapy; adjuvant therapy; palliative therapy

About this article
Title

Systemic therapy of colorectal cancer - consensus based on the results of clinical trials

Journal

Oncology in Clinical Practice

Issue

Vol 3, No 6 (2007)

Article type

Guidelines / Expert consensus

Pages

267-285

Published online

2008-05-08

Bibliographic record

Onkol. Prak. Klin 2007;3(6):267-285.

Keywords

colorectal cancer
systemic therapy
adjuvant therapy
palliative therapy

Authors

Maciej Krzakowski
Krzysztof Bujko
Kazimierz Drosik
Jacek Jassem
Krzysztof Krzemieniecki
Marek Wojtukiewicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl